bromocriptine

(redirected from Cycloset)
Also found in: Medical, Encyclopedia.
Related to Cycloset: bromocriptine

bro·mo·crip·tine

 (brō′mō-krĭp′tēn)
n.
An ergot alkaloid, C32H40BrN5O5, that is a dopamine antagonist and is used in its mesylate form to treat Parkinson's disease, acromegaly, and excessive prolactin secretion, and to reduce the size of certain pituitary tumors.

[bromo- + (ergo)cryptine, an ergot alkaloid (from German Ergokryptin : Ergo(t), ergot + Greek kruptos, hidden; see cryptic + -in, -in).]

bromocriptine

(ˌbrəʊməʊˈkrɪptiːn)
n
a dopamine agonist drug which blocks the release of prolactin from the pituitary gland, used in the treatment of Parkinson's disease
Translations

bromocriptine

n bromocriptina
References in periodicals archive ?
Patients with known hypersensitivity to bromocriptine, ergot-related drugs, or any of the excipients in CYCLOSET.
The Cycloset Safety Study included more than 3,000 patients with T2DM who received either bromocriptine QR or placebo, in conjunction with their usual diabetes therapy.
Cycloset, a quick-release oral formulation of bromocriptine mesylate, was recently approved by the Food and Drug Administration as a treatment for type 2 diabetes, according to the manufacturers, VeroScience and S2 Therapeutics Inc.
The company markets CYCLOSET tablets, and is working to commercialize GLUMETZA, drugs designed as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The company's current commercial efforts are focused on GLUMETZA (metformin hydrochloride extended release tablets) and CYCLOSET (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.
People don't have those seasonal variations but the theory is the dopamine plays a role anyway in sensitivity to insulin, although Cycloset apparently did not affect weight.
License fees and royalties include royalties on GLUMETZA net sales, the gross margin split on CYCLOSET net sales, royalties on ZEGERID net sales and amortization of upfront payments.
Cycloset is the first approved treatment for type 2 diabetes that seeks to improve dopamine activity in the brain--which studies have linked to better insulin control.
VeroScience holds the NDA and related intellectual property for Cycloset and has a large patent portfolio that supports its preclinical and clinical development programs and product pipeline in the areas of metabolism, immunology and oncology.
name of Cycloset tablet, from S2 Therapeutics and VeroScience, at five
Furthermore, among patients in the study, CYCLOSET significantly reduced the relative risk for the composite cardiovascular endpoint of myocardial infarction, stroke and cardiovascular death by 52%.
Vero is also conducting a clinical study to determine the effectiveness of Cycloset as add-on therapy in type 2 diabetes subjects whose blood sugar is not adequately controlled on Metformin therapy.